Suppr超能文献

离体大鼠心脏对钒酸盐变力性反应的机制

Mechanisms of inotropic responses of the isolated rat hearts to vanadate.

作者信息

Shah K R, Matsubara T, Foerster D R, Xu Y J, Dhalla N S

机构信息

Division of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada.

出版信息

Int J Cardiol. 1995 Nov 24;52(2):101-13. doi: 10.1016/0167-5273(95)02457-8.

Abstract

In view of the invariable development of insulin resistance in different types of cardiovascular diseases, considerable attention has been focused on vanadate because of its ability to exert insulin-like effects in the body. Since vanadate, like insulin, has been shown to exert a beneficial effect in diabetic cardiomyopathy, this study was undertaken to examine the mechanisms of its action on the heart. Vanadate, at 5-10 microM concentrations, produced a positive inotropic effect in the isolated perfused rat heart, whereas at higher concentrations (20 microM), it decreased the contractile force development. The positive inotropic effect of 10 microM vanadate was not affected by the pretreatment of animals with reserpine as well as the presence of propranolol or phenoxybenzamine in the perfusion medium. The increase in contractile force development due to vanadate at low (0.3-0.6 mM) concentrations of Ca2+ was markedly augmented, but this agent produced a negative inotropic action at high concentrations of Ca2+ (2.0-3.0 mM). Preperfusion of hearts with verapamil enhanced the positive inotropic effect of vanadate whereas hearts preperfused with ouabain, low sodium or amiloride showed negative inotropic effects of vanadate. Vanadate was found to inhibit sarcoplasmic reticular Ca(2+)-pump and sarcolemmal Ca(2+)-pump as well as Na(+)-K(+)-ATPase activities but the sarcolemmal effects were evident at lower concentrations in comparison to that on the sarcoplasmic reticulum. The actions of vanadate on membrane Ca2+ transport and ATPase systems were specific since this agent exerted no effect on sarcolemmal Na(+)-Ca2+ exchange or myofibrillar ATPase activities. In isolated cardiomyocytes suspended in buffer containing 0.5 or 1.0 mM Ca2+, vanadate increased the intracellular concentration of Ca2+; this increase in intracellular Ca2+ was more pronounced at 0.5 mM Ca2+. These results indicate that increased intracellular concentration of Ca2+ due to inhibition of sarcolemmal Na(+)-K(+)-ATPase and sarcolemmal Ca(2+)-pump may be the primary mechanism of the positive inotropic action of vanadate in the heart. It is suggested that vanadate may serve as an inotropic agent and that this mechanism may contribute towards its beneficial effects on cardiac dysfunction in different cardiovascular diseases.

摘要

鉴于不同类型心血管疾病中胰岛素抵抗的持续发展,钒酸盐因其在体内发挥类胰岛素作用的能力而受到了相当多的关注。由于钒酸盐与胰岛素一样,已被证明在糖尿病性心肌病中具有有益作用,因此开展了本研究以探讨其对心脏作用的机制。5 - 10微摩尔浓度的钒酸盐在离体灌注大鼠心脏中产生正性肌力作用,而在较高浓度(20微摩尔)时,它会降低收缩力的产生。10微摩尔钒酸盐的正性肌力作用不受利血平预处理动物以及灌注介质中普萘洛尔或酚苄明存在的影响。在低(0.3 - 0.6毫摩尔)浓度的Ca2+条件下,钒酸盐引起的收缩力增加显著增强,但在高浓度Ca2+(2.0 - 3.0毫摩尔)时该药物产生负性肌力作用。用维拉帕米预灌注心脏可增强钒酸盐的正性肌力作用,而用哇巴因、低钠或氨氯地平预灌注的心脏则显示出钒酸盐的负性肌力作用。发现钒酸盐可抑制肌浆网Ca(2 +)-泵和肌膜Ca(2 +)-泵以及Na(+)-K(+)-ATP酶活性,但与对肌浆网的作用相比,肌膜效应在较低浓度时就很明显。钒酸盐对膜Ca2+转运和ATP酶系统的作用具有特异性,因为该药物对肌膜Na(+)-Ca2+交换或肌原纤维ATP酶活性没有影响。在悬浮于含0.5或1.0毫摩尔Ca2+缓冲液中的离体心肌细胞中,钒酸盐增加了细胞内Ca2+浓度;在0.5毫摩尔Ca2+时细胞内Ca2+的这种增加更为明显。这些结果表明,由于抑制肌膜Na(+)-K(+)-ATP酶和肌膜Ca(2 +)-泵导致细胞内Ca2+浓度升高可能是钒酸盐在心脏中产生正性肌力作用的主要机制。有人提出钒酸盐可能作为一种正性肌力药物,并且这种机制可能有助于其对不同心血管疾病中的心脏功能障碍产生有益影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验